Berndt Modig, CEO, and Dr. Jochen Knolle, CSO, discuss Pharvaris, a clinical-stage company focused on developing oral therapies for hereditary angioedema (HAE) patients. Hereditary angioedema is a rare and potentially life-threatening genetic condition with incidence between 1 in 10,000 and 1 in 50,000 people. Current therapies are limited by invasive routes of drug administration (injection or […]

Initial safety data of STRO-002 shows potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models were presented at the AACR-NCI-EORTC.FRα is overexpressed in 80% of ovarian and endometrial carcinoma and shows minimal expression in normal tissues. STRO-002 is a folate receptor alpha (FolRα-) targeting antibody-drug conjugate (ADC) being developed by San Francisco-based Sutro Biopharma […]

The St. Louis-based startup, Wugen, is developing “off the shelf” medicine to treat various cancers. The company was created from technology licensed from Washington University researchers […]